193 related articles for article (PubMed ID: 31286808)
1. Survivors' knowledge of their diagnosis, treatment and possible late adverse effects after autologous stem cell transplantation for lymphoma.
Simensen VC; Smeland KB; Kiserud CE; Dahl AA; Bersvendsen HS; Fluge Ø; Fagerli UM; Fosså A
Acta Oncol; 2019 Sep; 58(9):1315-1322. PubMed ID: 31286808
[No Abstract] [Full Text] [Related]
2. Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes.
Bersvendsen HS; Haugnes HS; Fagerli UM; Fluge Ø; Holte H; Smeland KB; Wilsgaard T; Kiserud CE
Acta Oncol; 2019 May; 58(5):690-699. PubMed ID: 30696346
[No Abstract] [Full Text] [Related]
3. Post-treatment work patterns amongst survivors of lymphoma treated with high-dose chemotherapy with autologous stem-cell transplantation.
Hernæs KH; Smeland KB; Fagerli UM; Kiserud CE
BMC Cancer; 2021 Feb; 21(1):143. PubMed ID: 33557789
[TBL] [Abstract][Full Text] [Related]
4. Adult survivors of childhood malignant lymphoma are not aware of their risk of late effects.
Hess SL; Jóhannsdóttir IM; Hamre H; Kiserud CE; Loge JH; Fosså SD
Acta Oncol; 2011 Jun; 50(5):653-9. PubMed ID: 21261507
[TBL] [Abstract][Full Text] [Related]
5. Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation.
Kiserud CE; Fagerli UM; Smeland KB; Fluge Ø; Bersvendsen H; Kvaløy S; Holte H; Dahl AA
Acta Oncol; 2016 May; 55(5):547-53. PubMed ID: 27123741
[TBL] [Abstract][Full Text] [Related]
6. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.
Sun L; Li S; El-Jawahri A; Armand P; Dey BR; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; McAfee SL; Spitzer TR; Chen YB; DeFilipp Z
Oncologist; 2018 May; 23(5):624-630. PubMed ID: 29284757
[TBL] [Abstract][Full Text] [Related]
7. Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation.
Stenehjem JS; Smeland KB; Murbraech K; Holte H; Kvaløy SO; Wethal T; Kiserud CE; Samersaw-Lund MB
Acta Oncol; 2018 Jun; 57(6):773-781. PubMed ID: 29171324
[TBL] [Abstract][Full Text] [Related]
8. Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life.
Smeland K; Holte H; Fagerli UM; Bersvendsen H; Hjermstad MJ; Loge JH; Murbrach K; Linnsund MD; Fluge O; Stenehjem JS; Lund MB; Kvaloy S; Kiserud CE
Haematologica; 2022 Nov; 107(11):2698-2707. PubMed ID: 35484681
[TBL] [Abstract][Full Text] [Related]
9. Childhood and adolescent cancer survivors' knowledge of their disease and effects of treatment.
Bashore L
J Pediatr Oncol Nurs; 2004; 21(2):98-102. PubMed ID: 15125553
[TBL] [Abstract][Full Text] [Related]
10. Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis.
Owattanapanich W; Suphadirekkul K; Kunacheewa C; Ungprasert P; Prayongratana K
BMC Cancer; 2018 Nov; 18(1):1126. PubMed ID: 30445930
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.
Myers RM; Hill BT; Shaw BE; Kim S; Millard HR; Battiwalla M; Majhail NS; Buchbinder D; Lazarus HM; Savani BN; Flowers MED; D'Souza A; Ehrhardt MJ; Langston A; Yared JA; Hayashi RJ; Daly A; Olsson RF; Inamoto Y; Malone AK; DeFilipp Z; Margossian SP; Warwick AB; Jaglowski S; Beitinjaneh A; Fung H; Kasow KA; Marks DI; Reynolds J; Stockerl-Goldstein K; Wirk B; Wood WA; Hamadani M; Satwani P
Cancer; 2018 Feb; 124(4):816-825. PubMed ID: 29125192
[TBL] [Abstract][Full Text] [Related]
12. Impact of Tailored Education on Awareness of Personal Risk for Therapy-Related Complications Among Childhood Cancer Survivors.
Landier W; Chen Y; Namdar G; Francisco L; Wilson K; Herrera C; Armenian S; Wolfson JA; Sun CL; Wong FL; Bhatia S
J Clin Oncol; 2015 Nov; 33(33):3887-93. PubMed ID: 26324371
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.
Scordo M; Bhatt V; Hsu M; Omuro AM; Matasar MJ; DeAngelis LM; Dahi PB; Moskowitz CH; Giralt SA; Sauter CS
Biol Blood Marrow Transplant; 2017 Jan; 23(1):38-43. PubMed ID: 27713090
[TBL] [Abstract][Full Text] [Related]
14. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
Ruiz-Soto R; Sergent G; Gisselbrecht C; Larghero J; Ertault M; Hennequin C; Manson J; de Kerviler E; Briere J; Mounier N
Cancer; 2005 Dec; 104(12):2735-42. PubMed ID: 16284986
[TBL] [Abstract][Full Text] [Related]
15. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
16. High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era.
Blaker YN; Eide MB; Liestøl K; Lauritzsen GF; Kolstad A; Fosså A; Smeland EB; Holte H
Leuk Lymphoma; 2014 Oct; 55(10):2319-27. PubMed ID: 24432894
[TBL] [Abstract][Full Text] [Related]
17. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
[TBL] [Abstract][Full Text] [Related]
18. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation.
Levis M; Piva C; Filippi AR; Botto B; Gavarotti P; Pregno P; Nicolosi M; Freilone R; Parvis G; Gottardi D; Vitolo U; Ricardi U
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):14-22. PubMed ID: 27727134
[TBL] [Abstract][Full Text] [Related]
19. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
William BM; Loberiza FR; Whalen V; Bierman PJ; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
